Search

Displaying results 7051 - 7060 of 10000 in total
  1. Drug

    Nelmastobart

    go.drugbank.com/drugs/DB19000
    Investigational

    Nelmastobart is under investigation in clinical trial NCT05990543 (Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer).

  2. Drug

    Gamma cyclodextrin

    go.drugbank.com/drugs/DB19173
    Investigational

    Gamma cyclodextrin is under investigation in clinical trial NCT03931057 (The use of ADV6209 for Premedication in Pediatric Anesthesia).

  3. Drug

    Solrikitug

    go.drugbank.com/drugs/DB19301
    Investigational

    Solrikitug is under investigation in clinical trial NCT06496607 (A Study to Evaluate Solriktug in Adult Participants With Asthma).

  4. Drug

    Flufenoxuron

    go.drugbank.com/drugs/DB15006
    Experimental

    Flufenoxuron is under investigation in clinical trial NCT00922870 (Evaluation of Hemodynamic Effects of Cascade Hemofiltration in Septic Shock).

  5. Drug

    BPI-3016

    go.drugbank.com/drugs/DB15158
    Investigational

    BPI-3016 is under investigation in clinical trial NCT03188848 (Dose Escalating Study of BPI-3016 in Healthy Subjects).

  6. Drug

    Telaglenastat

    go.drugbank.com/drugs/DB15232
    Investigational

    Telaglenastat is under investigation in clinical trial NCT02071862 (Study of the Glutaminase Inhibitor CB-839 in Solid Tumors).

  7. Drug

    Dihematoporphyrin ether

    go.drugbank.com/drugs/DB15351
    Investigational

    Dihematoporphyrin ether is under investigation in clinical trial NCT00118222 (High Light and Low Light Dose PDT in Glioma).

  8. Drug

    Egaptivon pegol

    go.drugbank.com/drugs/DB05202
    Investigational

    Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets.

  9. Drug

    KP-1461

    go.drugbank.com/drugs/DB05644
    Investigational

    KP-1461 is a potent, non-chain-terminating, mutagenic deoxyribonucleoside analogue. Designated a DNA covert nucleoside, the drug consists of a modified base that incorporates randomly into HIV and pairs with multiple bases.

  10. Drug

    Cobolimab

    go.drugbank.com/drugs/DB16372
    Investigational

    Cobolimab is under investigation in clinical trial NCT04655976 (Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants).